Utama › Leukemia Limfositik Kronik › Michigan
Kajian klinikal Leukemia Limfositik Kronik di Michigan
12 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi di Michigan.
Bandar di Michigan
- Detroit7 kajian
- Grand Rapids5 kajian
- Lansing3 kajian
- Livonia3 kajian
- Ann Arbor3 kajian
- Canton3 kajian
- Waterford3 kajian
- Kalamazoo3 kajian
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 65 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- dan 68 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- dan 43 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- The Cancer and Hematology Centers, Grand Rapids
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Karmanos Cancer Institute, Detroit
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Corewell Health the Michigan Cancer Consortium, Grand Rapids
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Karmanos Cancer Institute, Detroit
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Karmanos Cancer Center, Detroit
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07221500Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- West Michigan Cancer Center, Kalamazoo
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mei 2026 · NCT02269592A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Henry Ford Hospital /ID# 270973, Detroit
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Apr 2026 · NCT06428019HPC Offered for PRESERVE Expansion
- Henry Ford Health, Detroit
Mengambil pesertaKajian pemerhatian
Umur 12 hingga 80 · Semua jantina · Dikemas kini 28 Ogo 2025 · NCT07145411Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.